دورية أكاديمية
UDP-glucuronosyltransferases and biochemical recurrence in prostate cancer progression
| العنوان: | UDP-glucuronosyltransferases and biochemical recurrence in prostate cancer progression |
|---|---|
| المؤلفون: | Delores J. Grant, Zinan Chen, Lauren E. Howard, Emily Wiggins, Amanda De Hoedt, Adriana C. Vidal, Skyla T. Carney, Jill Squires, Clara E. Magyar, Jiaoti Huang, Stephen J. Freedland |
| المصدر: | BMC Cancer, Vol 17, Iss 1, Pp 1-8 (2017) |
| بيانات النشر: | BMC |
| سنة النشر: | 2017 |
| المجموعة: | Directory of Open Access Journals: DOAJ Articles |
| مصطلحات موضوعية: | Prostate cancer, Biochemical recurrence, UDP-glucuronosyltransferases, UGT2B17, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282 |
| الوصف: | Background Uridine 5′-diphosphate-glucuronosyltransferase 2B (UGT2B) genes code for enzymes that catalyze the clearance of testosterone, dihydrotestosterone (DHT), and DHT metabolites in the prostate basal and luminal tissue. The expression of the UGT2B15, UGT2B17, and UGT2B28 enzymes has not been evaluated in prostate tissue samples from hormone therapy-naïve patients. Methods We determined the expression of UGT2B15, UGT2B17, and UGT2B28 enzymes in 190 prostate tissue samples from surgical specimens of a multiethnic cohort of patients undergoing radical prostatectomy at the Durham Veterans Affairs Medical Center. The association between each protein’s percent positive and H-score, a weighted score of staining intensity, and the risk of biochemical recurrence (BCR) was tested using separate Cox proportional hazards models. In an exploratory analysis, UGT2B17 total positive and H-score were divided at the median and we tested the association between UGT2B17 group and risk of BCR. Results The median follow-up for all patients was 118 months (IQR: 85-144). Of 190, 83 (44%) patients developed BCR. We found no association between UGT2B15 or UGT2B28 and risk of BCR. However, there was a trend for an association between UGT2B17 and BCR (HR = 1.01, 95% CI 1.00-1.02, p = 0.11), though not statistically significant. Upon further investigation, we found that patients with UGT2B17 higher levels of expression had a significant increased risk of BCR on univariable analysis (HR = 1.57, 95% CI 1.02-2.43, p = 0.041), although this association was attenuated in the multivariable model (HR = 1.50, 95% CI 0.94-2.40, p = 0.088). Conclusions Our findings suggest that UGT2B17 overexpression may be associated with a significant increased risk of BCR. These results are consistent with previous reports which showed UGT2B17 significantly expressed in advanced prostate cancer including prostate tumor metastases. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| تدمد: | 1471-2407 |
| العلاقة: | http://link.springer.com/article/10.1186/s12885-017-3463-6Test; https://doaj.org/toc/1471-2407Test; https://doaj.org/article/5419a6935b584351a2cc57bda30313c7Test |
| DOI: | 10.1186/s12885-017-3463-6 |
| الإتاحة: | https://doi.org/10.1186/s12885-017-3463-6Test https://doaj.org/article/5419a6935b584351a2cc57bda30313c7Test |
| رقم الانضمام: | edsbas.9957DC15 |
| قاعدة البيانات: | BASE |
Full Text Finder | تدمد: | 14712407 |
|---|---|
| DOI: | 10.1186/s12885-017-3463-6 |